instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'SULFAMETHOXAZOLE\TRIMETHOPRIM'? | Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome.
Case reports, case series and cohort studies have been published describing the clinical course an... | UNKNOWN | DrugDosageText | CC BY-NC-ND | 33977081 | 19,470,652 | 2021 |
What was the dosage of drug 'TENOFOVIR ALAFENAMIDE'? | Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome.
Case reports, case series and cohort studies have been published describing the clinical course an... | UNKNOWN | DrugDosageText | CC BY-NC-ND | 33977081 | 19,470,652 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac arrest'. | Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial.
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese p... | CYTARABINE, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY-NC-SA | 33979972 | 19,376,789 | 2021-04-14 |
What was the administration route of drug 'CYTARABINE'? | Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial.
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese p... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-SA | 33979972 | 19,376,789 | 2021-04-14 |
What was the dosage of drug 'CYTARABINE'? | Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial.
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese p... | 20 MG/M2,LOW DOSE, CYCLIC (ONCE A DAY FROM DAY 1 TO DAY 10 OF ALL CYCLES) | DrugDosageText | CC BY-NC-SA | 33979972 | 19,376,789 | 2021-04-14 |
What was the dosage of drug 'UNSPECIFIED INGREDIENT'? | Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial.
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese p... | UNK UNK, CYCLIC | DrugDosageText | CC BY-NC-SA | 33979972 | 19,376,789 | 2021-04-14 |
What was the outcome of reaction 'Cardiac arrest'? | Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial.
Objective: To investigate the safety and efficacy of venetoclax with low-dose cytarabine (LDAC) in Chinese p... | Fatal | ReactionOutcome | CC BY-NC-SA | 33979972 | 19,376,789 | 2021-04-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Accidental overdose'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | CEFAZOLIN, DAPTOMYCIN, DEXAMETHASONE, DIPHENOXYLATE, IXAZOMIB, LENALIDOMIDE, LOPERAMIDE, METRONIDAZOLE, NOREPINEPHRINE, VANCOMYCIN | DrugsGivenReaction | CC BY-NC | 33980053 | 19,307,404 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enteritis'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product administration error'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Staphylococcal infection'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | CEFAZOLIN, DAPTOMYCIN, DEXAMETHASONE, DIPHENOXYLATE, IXAZOMIB, LENALIDOMIDE, LOPERAMIDE, METRONIDAZOLE, NOREPINEPHRINE, VANCOMYCIN | DrugsGivenReaction | CC BY-NC | 33980053 | 19,307,404 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxicity to various agents'. | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | DEXAMETHASONE, IXAZOMIB CITRATE, LENALIDOMIDE, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33980053 | 19,305,631 | 2021 |
What was the administration route of drug 'DAPTOMYCIN'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the administration route of drug 'DEXAMETHASONE'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Oral | DrugAdministrationRoute | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the administration route of drug 'IXAZOMIB CITRATE'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Oral | DrugAdministrationRoute | CC BY-NC | 33980053 | 19,305,631 | 2021 |
What was the administration route of drug 'IXAZOMIB'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Oral | DrugAdministrationRoute | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the administration route of drug 'LENALIDOMIDE'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Oral | DrugAdministrationRoute | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the dosage of drug 'NOREPINEPHRINE'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | INFUSION | DrugDosageText | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the outcome of reaction 'Diarrhoea'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Recovering | ReactionOutcome | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the outcome of reaction 'Rash macular'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Recovering | ReactionOutcome | CC BY-NC | 33980053 | 19,307,404 | 2021 |
What was the outcome of reaction 'Staphylococcal infection'? | Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of o... | Recovered | ReactionOutcome | CC BY-NC | 33980053 | 19,307,404 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN, GEMCITABINE, PREDNISOLONE, VINCRISTINE | DrugsGivenReaction | CC BY | 33980166 | 19,401,832 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | CISPLATIN, CYCLOPHOSPHAMIDE, DEXAMETHASONE, DOXORUBICIN, GEMCITABINE, PREDNISOLONE, VINCRISTINE | DrugsGivenReaction | CC BY | 33980166 | 19,401,832 | 2021-05-12 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | 2 CYCLES | DrugDosageText | CC BY | 33980166 | 19,401,832 | 2021-05-12 |
What was the dosage of drug 'DOXORUBICIN'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | 2 CYCLICAL | DrugDosageText | CC BY | 33980166 | 19,401,832 | 2021-05-12 |
What was the dosage of drug 'GEMCITABINE HYDROCHLORIDE'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | 1000 MG/M2 ON DAYS 1 AND 8 | DrugDosageText | CC BY | 33980166 | 19,363,466 | 2021-05-12 |
What was the dosage of drug 'GEMCITABINE\GEMCITABINE HYDROCHLORIDE'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | 1000 MG/M2 OF GEMCITABINE ON DAYS 1 AND 8 | DrugDosageText | CC BY | 33980166 | 19,332,476 | 2021-05-12 |
What was the dosage of drug 'PREDNISOLONE'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | 2 CYCLES | DrugDosageText | CC BY | 33980166 | 19,401,832 | 2021-05-12 |
What was the dosage of drug 'VINCRISTINE'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | 2 CYCLES | DrugDosageText | CC BY | 33980166 | 19,401,832 | 2021-05-12 |
What was the outcome of reaction 'Acute kidney injury'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | Recovered | ReactionOutcome | CC BY | 33980166 | 19,332,476 | 2021-05-12 |
What was the outcome of reaction 'Anaemia'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | Recovered | ReactionOutcome | CC BY | 33980166 | 19,332,476 | 2021-05-12 |
What was the outcome of reaction 'Condition aggravated'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | Recovered | ReactionOutcome | CC BY | 33980166 | 19,332,476 | 2021-05-12 |
What was the outcome of reaction 'Inflammation'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | Recovered | ReactionOutcome | CC BY | 33980166 | 19,332,476 | 2021-05-12 |
What was the outcome of reaction 'Renal-limited thrombotic microangiopathy'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | Recovered | ReactionOutcome | CC BY | 33980166 | 19,363,466 | 2021-05-12 |
What was the outcome of reaction 'Urinary casts'? | Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but... | Recovered | ReactionOutcome | CC BY | 33980166 | 19,332,476 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Capillary leak syndrome'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cough'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, METHYLPREDNISOLONE, PREDNISOLONE | DrugsGivenReaction | CC BY | 33980211 | 19,423,489 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | BASILIXIMAB, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,518,109 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Headache'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tachypnoea'. | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | ACETAMINOPHEN, ALEMTUZUMAB, ALLOPURINOL, CLEMASTINE, FUROSEMIDE, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the administration route of drug 'ALEMTUZUMAB'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Subcutaneous | DrugAdministrationRoute | CC BY | 33980211 | 19,423,489 | 2021-05-12 |
What was the administration route of drug 'FUROSEMIDE'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33980211 | 19,518,109 | 2021-05-12 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33980211 | 19,518,109 | 2021-05-12 |
What was the dosage of drug 'FUROSEMIDE'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | 80 mg (milligrams). | DrugDosage | CC BY | 33980211 | 19,518,109 | 2021-05-12 |
What was the outcome of reaction 'Acute kidney injury'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Acute respiratory distress syndrome'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Capillary leak syndrome'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Circulatory collapse'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Cough'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Dyspnoea'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Haemoptysis'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Headache'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Oedema'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Off label use'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Pulmonary oedema'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Pyrexia'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Respiratory failure'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
What was the outcome of reaction 'Tachypnoea'? | Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report.
Alemtuzumab is a T cell depleting antibody agent used as induction immunosuppressant therapy in solid organ transplant recipients. In addition, it is being... | Recovering | ReactionOutcome | CC BY | 33980211 | 19,297,345 | 2021-05-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Ozone therapy as an alternative method for the treatment of diabetic foot ulcer: a case report.
BACKGROUND
Diabetic foot ulcer (DFU) is one of the most important complications of diabetes that can lead to amputation. Treatment of DFUs is a major challenge and places a heavy economic and social burden on patients and th... | CEFAZOLIN, CEPHALEXIN, CIPROFLOXACIN, CLINDAMYCIN, GLYBURIDE, LEVOTHYROXINE SODIUM, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33980300 | 20,460,353 | 2021-05-13 |
What was the administration route of drug 'CIPROFLOXACIN'? | Ozone therapy as an alternative method for the treatment of diabetic foot ulcer: a case report.
BACKGROUND
Diabetic foot ulcer (DFU) is one of the most important complications of diabetes that can lead to amputation. Treatment of DFUs is a major challenge and places a heavy economic and social burden on patients and th... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33980300 | 20,460,353 | 2021-05-13 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Conjunctivalisation'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Conjunctivitis'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Corneal neovascularisation'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Corneal opacity'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Corneal scar'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diplopia'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eye inflammation'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Eyelid irritation'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Limbal stem cell deficiency'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Scleral disorder'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin exfoliation'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Symblepharon'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Trichiasis'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vision blurred'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Visual impairment'. | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | DUPILUMAB | DrugsGivenReaction | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the administration route of drug 'DUPILUMAB'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Conjunctivalisation'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Conjunctivitis'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Recovering | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Corneal neovascularisation'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Corneal opacity'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Corneal scar'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Diplopia'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Eye inflammation'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Eyelid irritation'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Recovering | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Limbal stem cell deficiency'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Scleral disorder'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Skin exfoliation'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Recovering | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
What was the outcome of reaction 'Symblepharon'? | Dupilumab Induced Limbal Stem Cell Deficiency.
Dupilumab is a monoclonal antibody that is used for the treatment of atopic dermatitis (AD) in adults. However, increasing reports of ocular complications including conjunctivitis and dry eye disease have been documented. In this report, we describe a case of a patient who... | Not recovered | ReactionOutcome | CC BY-NC | 33981166 | 19,374,980 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.